EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Multicenter Real‐World Evaluation of Neoadjuvant Carboplatin in Triple‐Negative Breast Cancer

Halil İbrahim Ellez iD, Eda ÇalişkanYildirim iD, Nargiz Majidova iD, Yeşim Ağyol iD, Murat Sarı iD, Hüseyin Salih Semiz iD, Oktay Halit Aktepe iD, Olçun Umit Unal iD, Elif Atağ iD

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71951 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 21.05.2026. Verfasst von Halil İbrahim Ellez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departmant of Medical Oncology, Sanlıurfa Mehmet Akif İnan Education and Research Hospital, University of Health Sciences, Sanlıurfa, Türkiye. Hauptthemen laut MEDLINE: Carboplatin, Triple Negative Breast Neoplasms, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The role of carboplatin in neoadjuvant chemotherapy for triple‐negative breast cancer (TNBC) remains controversial, particularly in settings where access to immunotherapy is limited. This study evaluated the real‐world impact of adding carboplatin to neoadjuvant chemotherapy on pathological complete response (pCR) and survival outcomes in patients with TNBC.

Methods

This retrospective multicenter study included patients with nonmetastatic TNBC treated with neoadjuvant anthracycline‐ and taxane‐based chemotherapy between 2018 and 2023 at three oncology centers in Turkey. Patients were grouped according to receipt of platinum‐containing therapy. Survival outcomes were estimated using the Kaplan–Meier method and compared with the log‐rank test. Cox regression analyses were performed to evaluate factors associated with survival. Propensity score matching was also performed as a supportive analysis.

Results

A total of 142 patients were included, of whom 45 (32.2%) received platinum‐containing neoadjuvant chemotherapy. Overall, 80 patients (56.3%) achieved pCR. The pCR rate was significantly higher in the platinum group than in the non‐platinum group (68.9% vs. 50.5%, p = 0.031). After a median follow‐up of 57 months, 24 deaths and 33 DFS events were observed. Median OS and DFS were not reached. The 60‐month OS rate was 96.0% in the platinum group and 73.9% in the non‐platinum group (log‐rank p = 0.027), whereas the 60‐month DFS rates were 86.1% and 67.6%, respectively (log‐rank p = 0.139). Patients who achieved pCR had significantly better OS and DFS than those with residual disease. In the propensity score‐matched cohort, non‐platinum treatment remained associated with inferior OS and DFS.

Conclusions

In this multicenter real‐world cohort, carboplatin was associated with a higher pCR rate and numerically favorable survival outcomes. These findings may be clinically relevant where immunotherapy is not readily accessible but should be considered hypothesis‐generating and require prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarboplatinTriple Negative Breast NeoplasmsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesPathologic Complete ResponseMiddle AgedAdultAgedTurkey

Stichwörter der Autor:innen

carboplatinneoadjuvant chemotherapyoverall survivalpathological complete responsetriple‐negative breast cancer

Substanzen

Carboplatin

Autor:innen und Institutionen

  • Departmant of Medical Oncology, Sanlıurfa Mehmet Akif İnan Education and Research Hospital, University of Health Sciences, Sanlıurfa, Türkiye.
  • Department of Medical Oncology, Sincan Education and Research Hospital, Ankara, Türkiye.
  • Department of Medical Oncology, VM Medical Park Maltepe Hospital, Istanbul, Türkiye.
  • Faculty of Medicine, Department of Medical Oncology, Marmara University, Istanbul, Türkiye.
  • Faculty of Medicine, Institute of Oncology, Dokuz Eylul University, Izmır, Türkiye.
  • Department of Medical Oncology, Izmir City Hospital, Izmır, Türkiye.

ORCID-Profile: Halil İbrahim Ellez, Eda ÇalişkanYildirim, Nargiz Majidova, Yeşim Ağyol, Murat Sarı, Hüseyin Salih Semiz, Oktay Halit Aktepe, Olçun Umit Unal, Elif Atağ

Zitieren

APA

Ellez, H. İ., ÇalişkanYildirim, E., Majidova, N., Ağyol, Y., Sarı, M., Semiz, H. S., Aktepe, O. H., Unal, O. U., & Atağ, E. (2026). Multicenter Real‐World Evaluation of Neoadjuvant Carboplatin in Triple‐Negative Breast Cancer. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71951

Vancouver

Ellez Hİ, ÇalişkanYildirim E, Majidova N, Ağyol Y, Sarı M, Semiz HS, et al. Multicenter Real‐World Evaluation of Neoadjuvant Carboplatin in Triple‐Negative Breast Cancer. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71951

BibTeX
@article{Ellez2026,
  author = {Ellez, Halil İbrahim and ÇalişkanYildirim, Eda and Majidova, Nargiz and Ağyol, Yeşim and Sarı, Murat and Semiz, Hüseyin Salih and Aktepe, Oktay Halit and Unal, Olçun Umit and Atağ, Elif},
  title = {Multicenter Real‐World Evaluation of Neoadjuvant Carboplatin in Triple‐Negative Breast Cancer},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71951}
}
Kostenlos starten →